Eiyzey / Vgenfli
Aflibercept biosimilar developed by Sam Chun Dang Pharm, development code SCD411. Reference product Eylea.
Brands by market: Eiyzey and Vgenfli (EU) · Commercial partner or holder: Polpharma (EU)
FDAnot listed
EMAAug 2025authorised
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Eiyzey
European Medicines Agency and European CommissionApprovedBrand
Eiyzey
Holder or applicant
Zaklady Farmaceutyczne Polpharma S.A.
Pathway
Centralised (Article 10(4))
Approved
Aug 2025
Application or permission
EMEA/H/C/006745
Presentations
see SmPC
Source
S017
EMA
European Union · Vgenfli
European Medicines Agency and European CommissionApprovedBrand
Vgenfli
Holder or applicant
Zaklady Farmaceutyczne Polpharma S.A.
Pathway
Centralised (Article 10(4))
Approved
Aug 2025
Application or permission
EMEA/H/C/006192
Presentations
see SmPC
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMAAug 2025Authorised by the European Commission as Eiyzey
- EMAAug 2025Authorised by the European Commission as Vgenfli
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning aflibercept biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.